You are here: Industry Insights > NMPA

News List

Weekly Pharmaceutical News Review | PharmaSources.com (Feb. 28th to March.4th) PharmaSources.com
March 16, 2022
The most talked-about news of this week is the successful overseas marketing of Nanjing LEGN.US's CAR-T, which not only demonstrates the strength of China's innovative biologics but also eases the anxiety of Chinese innovative drug companies.
Fighting Against COVID-19: Summary of Key Products PharmaSources/Recollect
February 22, 2022
Since the outbreak of COVID-19 in 2019, many kinds of COVID-19 vaccines, COVID-19 preventive drugs and COVID-19 therapeutic drugs have been approved worldwide.
Drug Marketing in China and Worldwide (March) PharmaSources
May 10, 2023
Summary of drug marketing at home and abroad (March)
With the help of Multiple Parties, the Pediatric Drugs Market Space has been Expanding PharmaSources/Yi
November 08, 2021
Recently, cyclophosphamide capsules of Hengrui Medicine and human growth hormone recombination injection of GeneScience Pharmaceuticals were proposed to be included in the priority review by CDE...
Analysis and Policy Review of Pediatric Drug Market of China PharmaSources/Zhulikou431
May 31, 2021
As mentioned in the previous article, the U.S. is currently the largest pediatric drug market in the world, followed by China.
This Japanese Enterprise Refused the Inspection of the Chinese Drug Regulator PharmaSources/Laoxue
September 23, 2020
The Japanese pharmaceutical enterprise: Sanyo Chemical Laboratories Co., Ltd.’s refusal of the NMPA’s inspection was disclosed and exposed by the NMPA on July 31.
Pharmaceutical News of the Week (July. 13th-July. 17th) | PharmaSources.com - Updates on Approvals PharmaSources/Caicai
July 22, 2020
With the third week of July coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions, and miscellany that happened during July 13-17, including 30 pieces.
Pharmaceutical News of the Week (June. 29th-July. 3rd) | PharmaSources.com - Updates on Policies PharmaSources/Caicai
July 08, 2020
Let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 29-July 3, including 29 pieces.
Second ADC Therapeutic Drug Was Approved for Marketing in China CPhI.CN
May 14, 2020
Takeda Pharmaceutical's application of vebutuximab for injection has been approved and became the second ADC drug approved in the Chinese market.
NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon C PR Newswire
February 24, 2025
Innovent's NDA for ipilimumab with sintilimab as neoadjuvant for MSI-H/dMMR colon cancer is accepted and gets Priority Review, based on trial results.